Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Zenuzolac (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GeneOne Life Science
- 27 Aug 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 11 Sep 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 25 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.